Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; School of Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan.
Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
J Formos Med Assoc. 2023 Feb;122(2):187-191. doi: 10.1016/j.jfma.2022.07.010. Epub 2022 Aug 18.
The appropriate interval between heterologous prime adenoviral vectored vaccination and boost mRNA vaccination remains unclear. We recruited 100 adult participants to receive a prime adenoviral vectored vaccine (ChAdOx1, AstraZeneca) and a boost mRNA vaccine (mRNA-1273, Moderna) 12 weeks apart and checked their serum SARS-CoV-2 anti-spike IgG titers and neutralizing antibody titers against B.1.1.7 (alpha) and B.1.617.2 (delta) variants on the 28 day after the boost dose. Results were compared with our previous study cohorts who received the same prime-boost vaccinations at 4- and 8-week intervals. Compared to other heterologous vaccination groups, the 12-week interval group had higher neutralizing antibody titers against SARS-CoV-2 variants than the 4-week interval group and was similar to the 8-week interval group at day 28. Adverse reactions after the boost dose were mild and transient. Our results support deploying viral vectored and mRNA vaccines in a flexible schedule with intervals from 8 to 12 weeks.
不同型别腺病毒载体疫苗初免-加强免疫的间隔时间仍不清楚。我们招募了 100 名成年人，间隔 12 周分别接种腺病毒载体疫苗（ChAdOx1，阿斯利康）和 mRNA 疫苗（mRNA-1273，莫德纳），并在加强免疫后第 28 天检测其血清 SARS-CoV-2 刺突 IgG 滴度和针对 B.1.1.7（阿尔法）和 B.1.617.2（德尔塔）变异株的中和抗体滴度。结果与我们之前的研究队列进行了比较，这些研究队列在 4 周和 8 周间隔时间接受了相同的初免-加强免疫。与其他异源疫苗接种组相比，12 周间隔组对 SARS-CoV-2 变异株的中和抗体滴度高于 4 周间隔组，与 8 周间隔组相似。加强免疫后不良反应轻微且短暂。我们的结果支持灵活安排病毒载体疫苗和 mRNA 疫苗的接种计划，间隔时间为 8 至 12 周。
